This included PD-L1 CAR T-cell activity against PD-L1+ MDA-MB-231 breast cancer cells (Fig. 7E) and EGFR variant III CAR T-cell activity against EGFRvIII+ U87 glioblastoma cell line (Fig. 7F). This evidence concerns the gene EGFR and breast carcinoma.